Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a sys...
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD.
Ovid MEDLINE, SCOPUS, and Cochrane Database of Systematic Reviews we...
Alternative Titles
Full title
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_80db7bcc9c9349068fe34e7259af32fb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_80db7bcc9c9349068fe34e7259af32fb
Other Identifiers
ISSN
1471-2369
E-ISSN
1471-2369
DOI
10.1186/s12882-020-01797-7
